DE60203026T2 - Sulfonylpyridazinone Derivate zur Behandlung von ischämischem Gewebeschaden - Google Patents

Sulfonylpyridazinone Derivate zur Behandlung von ischämischem Gewebeschaden Download PDF

Info

Publication number
DE60203026T2
DE60203026T2 DE60203026T DE60203026T DE60203026T2 DE 60203026 T2 DE60203026 T2 DE 60203026T2 DE 60203026 T DE60203026 T DE 60203026T DE 60203026 T DE60203026 T DE 60203026T DE 60203026 T2 DE60203026 T2 DE 60203026T2
Authority
DE
Germany
Prior art keywords
pyridazin
benzenesulfonyl
compound
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60203026T
Other languages
German (de)
English (en)
Other versions
DE60203026D1 (de
Inventor
Banavara L. Groton Mylari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60203026D1 publication Critical patent/DE60203026D1/de
Application granted granted Critical
Publication of DE60203026T2 publication Critical patent/DE60203026T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60203026T 2001-05-24 2002-05-22 Sulfonylpyridazinone Derivate zur Behandlung von ischämischem Gewebeschaden Expired - Fee Related DE60203026T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29339301P 2001-05-24 2001-05-24
US293393 2001-05-24

Publications (2)

Publication Number Publication Date
DE60203026D1 DE60203026D1 (de) 2005-03-31
DE60203026T2 true DE60203026T2 (de) 2006-05-04

Family

ID=23128899

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60203026T Expired - Fee Related DE60203026T2 (de) 2001-05-24 2002-05-22 Sulfonylpyridazinone Derivate zur Behandlung von ischämischem Gewebeschaden

Country Status (15)

Country Link
US (1) US6872722B2 (https=)
EP (1) EP1260224B1 (https=)
JP (1) JP2002370984A (https=)
KR (1) KR20020090321A (https=)
CN (1) CN1390547A (https=)
AT (1) ATE289510T1 (https=)
AU (1) AU761191B2 (https=)
CA (1) CA2387007A1 (https=)
CZ (1) CZ20021782A3 (https=)
DE (1) DE60203026T2 (https=)
ES (1) ES2236447T3 (https=)
HU (1) HUP0201738A3 (https=)
PL (1) PL354128A1 (https=)
SK (1) SK7332002A3 (https=)
ZA (1) ZA200203985B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
DK1961420T3 (da) * 2005-12-16 2012-08-27 Sanwa Kagaku Kenkyusho Co Middel til forebyggelse og behandling af akut nyresvigt
KR20080108465A (ko) * 2006-02-20 2008-12-15 가부시키가이샤산와카가쿠켄큐쇼 뇌졸중에 있어서의 뇌허혈 또는 뇌허혈 재관류 장해의 예방또는 치료제
WO2022197487A1 (en) 2021-03-18 2022-09-22 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH01258671A (ja) * 1987-12-01 1989-10-16 Morishita Pharmaceut Co Ltd ５−（１ｈ−イミダゾール−１−イル）−３（２ｈ）−ピリダジノン誘導体
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
WO1992017446A2 (en) * 1991-03-28 1992-10-15 Pfizer Inc. Pyridazinone acetic acids aldose reductase inhibitors
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
US5506228A (en) * 1995-02-23 1996-04-09 Merck & Co., Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
CN1142148C (zh) * 1997-11-19 2004-03-17 兴和株式会社 新颖的哒嗪衍生物和含有其作为有效成分的药物
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
CA2442476A1 (en) * 2001-03-30 2002-10-10 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors

Also Published As

Publication number Publication date
US6872722B2 (en) 2005-03-29
AU761191B2 (en) 2003-05-29
EP1260224B1 (en) 2005-02-23
JP2002370984A (ja) 2002-12-24
DE60203026D1 (de) 2005-03-31
CN1390547A (zh) 2003-01-15
CZ20021782A3 (cs) 2003-03-12
EP1260224A1 (en) 2002-11-27
HUP0201738A2 (hu) 2003-02-28
ES2236447T3 (es) 2005-07-16
HUP0201738A3 (en) 2003-11-28
ATE289510T1 (de) 2005-03-15
US20030008871A1 (en) 2003-01-09
ZA200203985B (en) 2003-11-20
PL354128A1 (en) 2002-12-02
KR20020090321A (ko) 2002-12-02
SK7332002A3 (en) 2003-05-02
AU4068502A (en) 2002-11-28
HU0201738D0 (https=) 2002-07-29
CA2387007A1 (en) 2002-11-24

Similar Documents

Publication Publication Date Title
EP0469013B1 (de) Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel
DE60009777T2 (de) Verbindung für Behandlung und Vorsorge bei Diabetes
DE60217930T2 (de) Pyridazinon Aldose Reductase Inhibitoren
DE69329787T2 (de) Antiarrhythmische und cardioprotektive substituierte 1(2H)-Isochinoline, Verfahren zu deren Herstellung, diese enthaltende Arzneimittel und ihre Anwendung für die Herstellung eines Arzneimittels zur Behandlung von Herzinsuffizienzen
EP0510562A1 (de) Neue Pyridazine
EP1347959A1 (de) Indol-derivate
EP0117403B1 (de) 6-(Acylaminoaryl)-3(2H)-pyridazinonderivate, ihre Herstellung und Verwendung
DE4243381B4 (de) 3(2H)-Pyridazinonderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung sowie diese enthaltende Arzneimittel und ihre Verwendung
EP0450359B1 (de) Herbizides Mittel
DE60203026T2 (de) Sulfonylpyridazinone Derivate zur Behandlung von ischämischem Gewebeschaden
DE60204611T2 (de) Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren
EP0144012B1 (de) Indolderivate
DE3049959C2 (https=)
DE3417391A1 (de) Pyridazinone, ihre herstellung und verwendung, pyridazinone enthaltende arzneimittel
DE60202969T2 (de) Substituierte alkylaminopyridazinonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP0012338A1 (de) Dihydropyridazinone, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende therapeutische Mittel
EP0174458A1 (de) Verwendung von 4H-1,4 Benzothiazinen bei der Prophylaxe und Therapie von Erkrankungen der Atemwege, Entzündungen/Rheuma, thromboembolischen Erkrankungen, Ischämien und Infarkten, Herzrhythmusstörungen, Arteriosklerose und Dermatosen, Arzneimittel zu diesem Zweck sowie Wirkstoffe, die in diesen Arnzeimitteln enthalten sind
EP0089528A1 (de) 6-Aryl-4,5-dihydro-3(2H)-pyridazinone,ihre Herstellung und Verwendung
DE3022177A1 (de) Neue dihydropyridazinone, verfahren zu ihrer herstellung und diese verbindung enthaltende therapeutische mittel
EP0228094B1 (de) Pyrimido[5,4-b][1,4]oxazinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel sowie Zwischenprodukte darstellende Pyrimido[5,4-b][1,4]oxazinderivate
DE69406763T2 (de) Pyridazinon Derivate, Herstellungsverfahren und Verwendung
EP0042513B1 (de) Neue Dihydropyridazinone, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende therapeutische Mittel
EP2349983B1 (de) Difluorphenyl-diacylhydrazid-derivate
WO1990001479A1 (de) 4,5-dihydro-3(2h)-pyridazinone, verfarhren zu ihrer herstellung und ihre verwendung
DE3129444A1 (de) "sulfoximine, deren herstellung und diese verbindungen enthaltende arzneimittel"

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee